Progress in circulating tumor cell capture and analysis: implications for cancer management

References

• Redding WH, Monaghan P, Imrie SF. Detection of micrometastases in patients with primary breast cancer. Lancet322(8362), 1271–1274 (1983).
   Google Scholar
• Cote RJ, Rosen PP, Lesser ML, Old LJ, Osborne MP. Prediction of early relapse in patients with operable breast cancer by detection of occult bone marrow micrometastases. J. Clin. Oncol.9(10), 1749–1756 (1991).
   PubMed Web of Science ®Google Scholar
• Balic M. Disseminated tumor cells as biomarkers for breast cancer. Biomark. Med.3(3), 215–217 (2009).
   Google Scholar
• Braun S, Vogl FD, Naume B et al. A pooled analysis of bone marrow micrometastasis in breast cancer. N. Engl. J. Med.353(8), 793–802 (2005).
   PubMed Web of Science ®Google Scholar
• Giuliano AE, Hawes D, Ballman KV et al. Association of occult metastases in sentinel lymph nodes and bone marrow with survival among women with early-stage invasive breast cancer. JAMA306(4), 385–393 (2011).
   Google Scholar
• Cristofanilli M, Budd GT, Ellis MJ et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N. Engl. J. Med.351(8), 781–791 (2004).
   PubMed Web of Science ®Google Scholar
• Bauernhofer T, Zenahlik S, Hofmann G et al. Association of disease progression and poor overall survival with detection of circulating tumor cells in peripheral blood of patients with metastatic breast cancer. Oncol. Rep.13(2), 179–184 (2005).
   PubMed Web of Science ®Google Scholar
• Miller MC, Doyle GV, Terstappen LW. Significance of circulating tumor cells detected by the cellsearch system in patients with metastatic breast colorectal and prostate cancer. J. Oncol.617421 (2010).
   Google Scholar
• Lin H, Balic M, Zheng S, Datar R, Cote RJ. Disseminated and circulating tumor cells: role in effective cancer management. Crit. Rev. Oncol. Hematol.77(1), 1–11 (2011).
   PubMedGoogle Scholar
• Lianidou ES, Markou A. Circulating tumor cells in breast cancer: detection systems, molecular characterization, and future challenges. Clin. Chem.57(9), 1242–1255 (2011).
   PubMed Web of Science ®Google Scholar
• Iinuma H, Okinaga K, Adachi M et al. Detection of tumor cells in blood using CD45 magnetic cell separation followed by nested mutant allele-specific amplification of p53 and K-ras genes in patients with colorectal cancer. Int. J. Cancer89(4), 337–344 (2000).
   PubMed Web of Science ®Google Scholar
• Trzpis M, Mclaughlin PM, De Leij LM, Harmsen MC. Epithelial cell adhesion molecule: more than a carcinoma marker and adhesion molecule. Am. J. Pathol.171(2), 386–395 (2007).
   PubMed Web of Science ®Google Scholar
• Went PT, Lugli A, Meier S et al. Frequent EpCam protein expression in human carcinomas. Hum. Pathol.35(1), 122–128 (2004).
   PubMed Web of Science ®Google Scholar
• Rosenberg R, Gertler R, Friederichs J et al. Comparison of two density gradient centrifugation systems for the enrichment of disseminated tumor cells in blood. Cytometry49(4), 150–158 (2002).
   PubMedGoogle Scholar
• Vona G, Sabile A, Louha M et al. Isolation by size of epithelial tumor cells: a new method for the immunomorphological and molecular characterization of circulating tumor cells. Am. J. Pathol.156(1), 57–63 (2000).
   PubMed Web of Science ®Google Scholar
• Fleischer RL. Cancer filter deja vu. Science318(5858), 1864 (2007).
   Google Scholar
• Paterlini-Brechot P, Benali NL. Circulating tumor cells (CTC) detection: clinical impact and future directions. Cancer Lett.253(2), 180–204 (2007).
   PubMed Web of Science ®Google Scholar
• Vona G, Estepa L, Beroud C et al. Impact of cytomorphological detection of circulating tumor cells in patients with liver cancer. Hepatology39(3), 792–797 (2004).
   PubMed Web of Science ®Google Scholar
• Lin HK, Zheng S, Williams AJ et al. Portable filter-based microdevice for detection and characterization of circulating tumor cells. Clin. Cancer Res.16(20), 5011–5018 (2010).
   PubMed Web of Science ®Google Scholar
• Zheng S, Lin H, Liu JQ et al. Membrane microfilter device for selective capture, electrolysis and genomic analysis of human circulating tumor cells. J. Chromatogr. A1162(2), 154–161 (2007).
   PubMed Web of Science ®Google Scholar
• Cote RJ, Beattie EJ, Chaiwun B et al. Detection of occult bone marrow micrometastases in patients with operable lung carcinoma. Ann. Surg.222(4), 415–423 (1995).
   PubMed Web of Science ®Google Scholar
• Gao X, Yang L, Petros JA, Marshall FF, Simons JW, Nie S. In vivo molecular and cellular imaging with quantum dots. Curr. Opin. Biotechnol.16(1), 63–72 (2005).
   PubMed Web of Science ®Google Scholar
• Balic M, Rapp N, Stanzer S et al. Novel immunofluorescence protocol for multimarker assessment of putative disseminating breast cancer stem cells. Appl. Immunohistochem. Mol. Morphol.19(1), 33–40 (2011).
   Google Scholar
• Mego M, Mani SA, Lee BN et al. Expression of epithelial–mesenchymal transition-inducing transcription factors in primary breast cancer: the effect of neoadjuvant therapy. Int. J. Cancer130(4), 808–816 (2011).
   Google Scholar
• Smith B, Selby P, Southgate J, Pittman K, Bradley C, Blair GE. Detection of melanoma cells in peripheral blood by means of reverse transcriptase and polymerase chain reaction. Lancet338(8777), 1227–1229 (1991).
   PubMed Web of Science ®Google Scholar
• Stathopoulou A, Gizi A, Perraki M et al. Real-time quantification of CK-19 mRNA-positive cells in peripheral blood of breast cancer patients using the lightcycler system. Clin. Cancer Res.9(14), 5145–5151 (2003).
   PubMed Web of Science ®Google Scholar
• Stathopoulou A, Ntoulia M, Perraki M et al. A highly specific real-time RT-PCR method for the quantitative determination of CK-19 mRNA positive cells in peripheral blood of patients with operable breast cancer. Int. J. Cancer119(7), 1654–1659 (2006).
   PubMed Web of Science ®Google Scholar
• Ignatiadis M, Kallergi G, Ntoulia M et al. Prognostic value of the molecular detection of circulating tumor cells using a multimarker reverse transcription-PCR assay for cytokeratin 19, mammaglobin A, and HER2 in early breast cancer. Clin. Cancer Res.14(9), 2593–2600 (2008).
   PubMed Web of Science ®Google Scholar
• Bostick PJ, Chatterjee S, Chi DD et al. Limitations of specific reverse-transcriptase polymerase chain reaction markers in the detection of metastases in the lymph nodes and blood of breast cancer patients. J. Clin. Oncol.16(8), 2632–2640 (1998).
   PubMed Web of Science ®Google Scholar
• Cristofanilli M, Hayes DF, Budd GT et al. Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer. J. Clin. Oncol.23(7), 1420–1430 (2005).
   PubMed Web of Science ®Google Scholar
• Hayes DF, Cristofanilli M, Budd GT et al. Circulating tumor cells at each follow-up time point during therapy of metastatic breast cancer patients predict progression-free and overall survival. Clin. Cancer Res.12(14 Pt 1), 4218–4224 (2006).
   PubMed Web of Science ®Google Scholar
• Danila DC, Heller G, Gignac GA et al. Circulating tumor cell number and prognosis in progressive castration-resistant prostate cancer. Clin. Cancer Res.13(23), 7053–7058 (2007).
   PubMed Web of Science ®Google Scholar
• Cohen SJ, Punt CJ, Iannotti N et al. Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. J. Clin. Oncol.26(19), 3213–3221 (2008).
   PubMed Web of Science ®Google Scholar
• Scher HI, Jia X, De Bono JS et al. Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial data. Lancet Oncol.10(3), 233–239 (2009).
   PubMed Web of Science ®Google Scholar
• US FDA. FDA Approval document Nr. K050245, March 15th 2005.
   Google Scholar
• Balic M, Dandachi N, Hofmann G et al. Comparison of two methods for enumerating circulating tumor cells in carcinoma patients. Cytometry B. Clin. Cytom.68(1), 25–30 (2005).
   PubMed Web of Science ®Google Scholar
• Saliba AE, Saias L, Psychari E et al. Microfluidic sorting and multimodal typing of cancer cells in self-assembled magnetic arrays. Proc. Natl Acad. Sci. USA107(33), 14524–14529 (2010).
   PubMed Web of Science ®Google Scholar
• Maheswaran S, Sequist LV, Nagrath S et al. Detection of mutations in EGFR in circulating lung-cancer cells. N. Engl. J. Med.359(4), 366–377 (2008).
   PubMed Web of Science ®Google Scholar
• Nagrath S, Sequist LV, Maheswaran S et al. Isolation of rare circulating tumour cells in cancer patients by microchip technology. Nature450(7173), 1235–1239 (2007).
   PubMed Web of Science ®Google Scholar
• Sequist LV, Nagrath S, Toner M, Haber DA, Lynch TJ. The CTC-chip: an exciting new tool to detect circulating tumor cells in lung cancer patients. J. Thorac. Oncol.4(3), 281–283 (2009).
   PubMed Web of Science ®Google Scholar
• Farace F, Massard C, Vimond N et al. A direct comparison of CellSearch and ISET for circulating tumour-cell detection in patients with metastatic carcinomas. Br. J. Cancer105(6), 847–853 (2011).
   PubMed Web of Science ®Google Scholar
• Zheng S, Lin HK, Lu B et al. 3D microfilter device for viable circulating tumor cell (CTC) enrichment from blood. Biomed. Microdevices13(1), 203–213 (2011).
   PubMed Web of Science ®Google Scholar
• Davis JA, Inglis DW, Morton KJ et al. Deterministic hydrodynamics: taking blood apart. Proc. Natl Acad. Sci. USA103(40), 14779–14784 (2006).
   Google Scholar
• Huang LR, Cox EC, Austin RH, Sturm JC. Continuous particle separation through deterministic lateral displacement. Science304(5673), 987–990 (2004).
   PubMed Web of Science ®Google Scholar
• Inglis DW, Davis JA, Austin RH, Sturm JC. Critical particle size for fractionation by deterministic lateral displacement. Lab Chip6(5), 655–658 (2006).
   PubMedGoogle Scholar
• Wang XB, Yang J, Huang Y, Vykoukal J, Becker FF, Gascoyne PR. Cell separation by dielectrophoretic field-flow-fractionation. Anal. Chem.72(4), 832–839 (2000).
   PubMed Web of Science ®Google Scholar
• Moon HS, Kwon K, Kim SI et al. Continuous separation of breast cancer cells from blood samples using multi-orifice flow fractionation (MOFF) and dielectrophoresis (DEP). Lab Chip11(6), 1118–1125 (2011).
   PubMed Web of Science ®Google Scholar
• Becker FF, Wang XB, Huang Y, Pethig R, Vykoukal J, Gascoyne PR. Separation of human breast cancer cells from blood by differential dielectric affinity. Proc. Natl Acad. Sci. USA92(3), 860–864 (1995).
   PubMed Web of Science ®Google Scholar
• Alazzam A, Stiharu I, Bhat R, Meguerditchian AN. Interdigitated comb-like electrodes for continuous separation of malignant cells from blood using dielectrophoresis. Electrophoresis32(11), 1327–1336 (2011).
   PubMed Web of Science ®Google Scholar
• Gascoyne PR, Noshari J, Anderson TJ, Becker FF. Isolation of rare cells from cell mixtures by dielectrophoresis. Electrophoresis30(8), 1388–1398 (2009).
   PubMed Web of Science ®Google Scholar
• Wicha MS, Liu S, Dontu G. Cancer stem cells: an old idea – a paradigm shift. Cancer Res.66(4), 1883–1890 (2006).
   PubMed Web of Science ®Google Scholar
• Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc. Natl Acad. Sci. USA100(7), 3983–3988 (2003).
   PubMed Web of Science ®Google Scholar
• Ginestier C, Hur MH, Charafe-Jauffret E et al. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell1(5), 555–567 (2007).
   PubMed Web of Science ®Google Scholar
• Balic M, Lin H, Young L et al. Most early disseminated cancer cells detected in bone marrow of breast cancer patients have a putative breast cancer stem cell phenotype. Clin. Cancer Res.12(19), 5615–5621 (2006).
   PubMed Web of Science ®Google Scholar
• Theodoropoulos PA, Polioudaki H, Agelaki S et al. Circulating tumor cells with a putative stem cell phenotype in peripheral blood of patients with breast cancer. Cancer Lett.288(1), 99–106 (2010).
   PubMed Web of Science ®Google Scholar
• Gradilone A, Naso G, Raimondi C et al. Circulating tumor cells (CTCs) in metastatic breast cancer (MBC): prognosis, drug resistance and phenotypic characterization. Ann. Oncol.22(1), 86–92 (2011).
   PubMed Web of Science ®Google Scholar
• Aktas B, Tewes M, Fehm T, Hauch S, Kimmig R, Kasimir-Bauer S. Stem cell and epithelial–mesenchymal transition markers are frequently overexpressed in circulating tumor cells of metastatic breast cancer patients. Breast Cancer Res.11(4), R46 (2009).
   PubMed Web of Science ®Google Scholar
• Wicha MS, Hayes DF. Circulating tumor cells: not all detected cells are bad and not all bad cells are detected. J. Clin. Oncol.29(12), 1508–1511 (2011).
   PubMed Web of Science ®Google Scholar
• Geigl JB, Speicher MR. Single-cell isolation from cell suspensions and whole genome amplification from single cells to provide templates for CGH analysis. Nat. Protoc.2(12), 3173–3184 (2007).
   Google Scholar
• Mathiesen RR, Fjelldal R, Liestol K et al. High resolution cost–effectives of copy number changes in disseminated tumor cells of patients with breast cancer. Int. J. Cancer doi:10.1002/ijc.26444 (2011) (Epub ahead of print).
   Google Scholar
• Chimonidou M, Strati A, Tzitzira A et al. DNA methylation of tumor suppressor and metastasis suppressor genes in circulating tumor cells. Clin. Chem.57(8), 1169–1177 (2011).
   PubMed Web of Science ®Google Scholar
• Markou A, Strati A, Malamos N, Georgoulias V, Lianidou ES. Molecular characterization of circulating tumor cells in breast cancer by a liquid bead array hybridization assay. Clin. Chem.57(3), 421–430 (2011).
   PubMed Web of Science ®Google Scholar
• Fehm T, Becker S, Duerr-Stoerzer S et al. Determination of HER2 status using both serum HER2 levels and circulating tumor cells in patients with recurrent breast cancer whose primary tumor was HER2 negative or of unknown HER2 status. Breast Cancer Res.9(5), R74 (2007).
   PubMed Web of Science ®Google Scholar
• Munzone E, Nole F, Goldhirsch A et al. Changes of HER2 status in circulating tumor cells compared with the primary tumor during treatment for advanced breast cancer. Clin. Breast Cancer10(5), 392–397 (2010).
   PubMed Web of Science ®Google Scholar
• Idirisinghe PK, Thike AA, Cheok PY et al. Hormone receptor and c-ERBB2 status in distant metastatic and locally recurrent breast cancer. Pathologic correlations and clinical significance. Am. J. Clin. Pathol.133(3), 416–429 (2010).
   Google Scholar
• Wilking U, Karlsson E, Skoog L et al. HER2 status in a population-derived breast cancer cohort: discordances during tumor progression. Breast Cancer Res. Treat.125(2), 553–561 (2011).
   PubMed Web of Science ®Google Scholar
• Somlo G, Lau SK, Frankel P et al. Multiple biomarker expression on circulating tumor cells in comparison to tumor tissues from primary and metastatic sites in patients with locally advanced/inflammatory, and Stage 4 breast cancer, using a novel detection technology. Breast Cancer Res. Treat.128(1), 155–163 (2011).
   PubMed Web of Science ®Google Scholar
• Dharmasiri U, Njoroge SK, Witek MA et al. High-throughput selection, enumeration, electrokinetic manipulation, and molecular profiling of low-abundance circulating tumor cells using a microfluidic system. Anal. Chem.83(6), 2301–2309 (2011).
   PubMed Web of Science ®Google Scholar
• Yang MJ, Chiu HH, Wang HM et al. Enhancing detection of circulating tumor cells with activating KRAS oncogene in patients with colorectal cancer by weighted chemiluminescent membrane array method. Ann. Surg. Oncol.17(2), 624–633 (2010).
   Google Scholar
• Iinuma H, Watanabe T, Mimori K et al. Clinical significance of circulating tumor cells, including cancer stem-like cells, in peripheral blood for recurrence and prognosis in patients with Dukes’ stage B and C colorectal cancer. J. Clin. Oncol.29(12), 1547–1555 (2011).
   PubMed Web of Science ®Google Scholar
• Reinholz MM, Kitzmann KA, Tenner KS et al. Cytokeratin-19 and mammaglobin gene expression in circulating tumor cells from metastatic breast cancer patients enrolled in North central cancer treatment group (NCCTG) trials, N0234/336/436/437. Clin. Cancer Res.17(22), 7183–7193 (2011).
   PubMed Web of Science ®Google Scholar
• Nole F, Munzone E, Zorzino L et al. Variation of circulating tumor cell levels during treatment of metastatic breast cancer: prognostic and therapeutic implications. Ann. Oncol.19(5), 891–897 (2008).
   PubMed Web of Science ®Google Scholar
• De Bono JS, Scher HI, Montgomery RB et al. Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin. Cancer Res.14(19), 6302–6309 (2008).
   PubMed Web of Science ®Google Scholar
• Krebs MG, Sloane R, Priest L et al. Evaluation and prognostic significance of circulating tumor cells in patients with non-small-cell lung cancer. J. Clin. Oncol.29(12), 1556–1563 (2011).
   PubMed Web of Science ®Google Scholar
• Budd GT, Cristofanilli M, Ellis MJ et al. Circulating tumor cells versus imaging – predicting overall survival in metastatic breast cancer. Clin. Cancer Res.12(21), 6403–6409 (2006).
   PubMed Web of Science ®Google Scholar
• Giuliano M, Giordano A, Jackson S et al. Circulating tumor cells as prognostic and predictive markers in metastatic breast cancer patients receiving first-line systemic treatment. Breast Cancer Res.13(3), R67 (2011).
   PubMed Web of Science ®Google Scholar
• Gaforio JJ, Serrano MJ, Sanchez-Rovira P et al. Detection of breast cancer cells in the peripheral blood is positively correlated with estrogen-receptor status and predicts for poor prognosis. Int. J. Cancer107(6), 984–990 (2003).
   PubMed Web of Science ®Google Scholar
• Sato N, Hayashi N, Imamura Y et al. Usefulness of transcription-reverse transcription concerted reaction method for detecting circulating tumor cells in patients with colorectal cancer. Ann. Surg. Oncol. doi:10.1245/s10434-011-1889-7 (2011) (Epub ahead of print).
   Google Scholar
• Stathopoulou A, Vlachonikolis I, Mavroudis D et al. Molecular detection of cytokeratin-19-positive cells in the peripheral blood of patients with operable breast cancer: evaluation of their prognostic significance. J. Clin. Oncol.20(16), 3404–3412 (2002).
   PubMed Web of Science ®Google Scholar
• Molloy TJ, Bosma AJ, Baumbusch LO et al. The prognostic significance of tumour cell detection in the peripheral blood versus the bone marrow in 733 early-stage breast cancer patients. Breast Cancer Res.13(3), R61 (2011).
   Google Scholar
• Molloy TJ, Devriese LA, Helgason HH et al. A multimarker QPCR-based platform for the detection of circulating tumour cells in patients with early-stage breast cancer. Br. J. Cancer104(12), 1913–1919 (2011).
   Google Scholar
• Matsusaka S, Suenaga M, Mishima Y et al. Circulating tumor cells as a surrogate marker for determining response to chemotherapy in Japanese patients with metastatic colorectal cancer. Cancer Sci.102(6), 1188–1192 (2011).
   PubMed Web of Science ®Google Scholar
• Papavasiliou P, Fisher T, Kuhn J, Nemunaitis J, Lamont J. Circulating tumor cells in patients undergoing surgery for hepatic metastases from colorectal cancer. Proc. (Bayl. Univ. Med. Cent.)23(1), 11–14 (2010).
   PubMedGoogle Scholar
• Rahbari NN, Aigner M, Thorlund K et al. Meta-analysis shows that detection of circulating tumor cells indicates poor prognosis in patients with colorectal cancer. Gastroenterology138(5), 1714–1726 (2010).
   PubMed Web of Science ®Google Scholar
• Helo P, Cronin AM, Danila DC et al. Circulating prostate tumor cells detected by reverse transcription-PCR in men with localized or castration-refractory prostate cancer: concordance with CellSearch assay and association with bone metastases and with survival. Clin. Chem.55(4), 765–773 (2009).
   PubMed Web of Science ®Google Scholar
• Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell144(5), 646–674 (2011).
   PubMed Web of Science ®Google Scholar
• Scheel C, Weinberg RA. Phenotypic plasticity and epithelial–mesenchymal transitions in cancer and normal stem cells? Int. J. Cancer129(10), 2310–2314 (2011).
   PubMed Web of Science ®Google Scholar
• Raimondi C, Gradilone A, Naso G et al. Epithelial–mesenchymal transition and stemness features in circulating tumor cells from breast cancer patients. Breast Cancer Res. Treat.130(2), 449–455 (2011).
   PubMed Web of Science ®Google Scholar
• Roche H, Vahdat LT. Treatment of metastatic breast cancer: second line and beyond. Ann. Oncol.22(5), 1000–1010 (2011).
   PubMed Web of Science ®Google Scholar
• Harris L, Fritsche H, Mennel R et al. American society of clinical oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J. Clin. Oncol.25(33), 5287–5312 (2007).
   PubMed Web of Science ®Google Scholar
• Cardoso F, Fallowfield L, Costa A, Castiglione M, Senkus E. Locally recurrent or metastatic breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann. Oncol.22(Suppl. 6), vi25–vi30 (2011).
   PubMed Web of Science ®Google Scholar